Tirzepatide in Primary Care Data Collection

Following a National Institute for Health and Care Excellence (NICE) Technology Appraisal (TA) publication (TA1026) on 23 December 2024, tirzepatide (Mounjaro®) was recommended for managing overweight and obesity, alongside a reduced-calorie diet and increased physical activity in adults. There is an established eligibility criteria that prescribing clinicians will need to adhere to. NHS England have devised a framework for commissioners to implement the NICE Technology Appraisal (NICE TA1026) and NICE Funding Variation for tirzepatide (Mounjaro®) for the management of weight during its first three years of delivery within the NHS.

This framework advises on eligible patient cohorts, prioritisation strategy and phased implementation of tirzepatide (Mounjaro®) in the primary care settings. It also outlines the funding allocations to Integrated Care Boards (ICBs) to ensure effective delivery and equitable access to treatment across NHS systems in line with the NICE funding variation implementation approach.

This data collection enables:

• collate the appropriate aggregated data for the reporting period from Integrated Care Boards in relation to the prescribing of Tirzepatide (Mounjaro®) in primary care settings
• to ensure prescribing activity aligns with the NICE TA and the NHS England (NHSE) Funding Variation (FV) around cohorting of patient's based on those with the highest clinical need
• to support in any onward reporting requests and inform financial allocations

Data will be collected via the Data Collections Framework 3 times a year (4 in the first year of implementation).  

Registered users will have access to the exact dates in the Data Collections Framework and will be contacted ahead of reporting periods.